Isoproterenol

Isoproterenol is a synthetic drug that belongs to the class of beta-adrenergic agonists. It is commonly used in the field of advanced pharmaceutical science and technology to treat various conditions such as bronchospasm, heart block, and cardiac arrest. Isoproterenol is also known as isoprenaline, and it works by stimulating the beta receptors found in the lungs, heart, and smooth muscle tissues. The drug is administered through inhalation, injection, or oral form depending on the condition being treated. In inhalation form, it is commonly used to treat acute bronchospasm associated with asthma and chronic obstructive pulmonary disease (COPD). Isoproterenol inhalation acts as a bronchodilator by relaxing the airway muscles, allowing more air to pass through the lungs. When given intravenously or intramuscularly, isoproterenol is used to treat heart block, a condition that results from an interruption in the electrical signals that control the heartbeat. The drug acts by stimulating the beta receptors found in the heart, increasing the heart rate and improving the heart's contractility. Despite its effectiveness in treating various conditions, isoproterenol is associated with some side effects including anxiety, hypertension, palpitations, and tremors. As a result, it should only be used under the supervision of a healthcare professional who can carefully monitor an individual's response to treatment. In conclusion, isoproterenol is an important drug in advanced pharmaceutical science and technology, providing benefit to individuals with a variety of heart and lung conditions. By enhancing sympathetic nervous system activity, the drug can help patients breathe easier and maintain a normal heartbeat. However, due to its associated risks, the drug should only be used when deemed necessary by a healthcare professional.

← Journal of Advanced Pharmaceutical Science And Technology

Related Articles

1 journal(s) found

Advanced Pharmaceutical Science And Technology

ISSN: 2328-0182
Type: Open Access Journal
Editor-in-Chief: Rajiv Kumar, Northeastern University & DFCI Harvard Medical School.
The journal aims to cover the latest outstanding developments and research being done in the world, thus ensuring its scientific priority and significance in the field of Pharmaceutical Science and Technology. We expect the field to grow beyond the current developments. We aim for the best.